USPTO serial 97016539
Serial No. 97016539
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 26, 2025
- Examiner
- JOHNSON, DANYTHE ELIZABETH HA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 97016539?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Devon E. White
Devon E. White Wyrick Robbins Yates & Ponton LLP4101 Lake Boone Trail Suite 300Raleigh, NC 27607United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software for processing, visualizing, storing and analyzing pre-clinical and clinical radiology and pathology image data in the fields of drug development and disease research; downloadable computer software for image data management purposes, namely, pre-clinical and clinical image database management and research subject records management; downloadable computer software for processing multi-modal imaging data; downloadable computer software for the processing, storage and analysis of multi-modal imaging data for quantitation and evaluation of biomarkers and drug candidates; downloadable software for the assessment of tumors for research through use of biomarkers | ACTIVE | — |
| 041 | Educational services, namely, developing, arranging and conducting educational programs, panel discussions and non-downloadable webinars in the fields of pharmaceuticals, biotechnology, pre-clinical and clinical trials, and medical research; educational services, namely, providing non-downloadable publications in the nature of blogposts and magazines, and non-downloadable literature in the nature of periodicals and books in the fields of pharmaceuticals, biotechnology, pre-clinical and clinical trials, and medical research | ACTIVE | — |
| 042 | Medical and scientific research, namely, conducting clinical trial services for others and pre-clinical trial services for others in the nature of testing of pharmaceuticals; pharmaceutical research and development services; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms; imaging services and pathology in support of pharmaceutical research and development, namely, research of disease and non-medical ultrasound imaging services, all for the research and development of pharmaceuticals; drug discovery services; conducting early evaluations in the field of new drugs; scientific investigations for medical research purposes; medical and scientific research laboratory services; medical and scientific research, namely, providing analysis of imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; research and development in the fields of medical imaging, pharmaceuticals and biotechnology; design, development, maintenance and updating of computer software for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; electronic storage of medical images; processing of medical images, namely, digital image interpretation for scientific research and medical research purposes, labeling, correction, restoration and enhancement; pathology services in support of drug development, namely, medical research regarding diseases for the purpose of developing drugs; hosting of a medical imaging analysis and visualization platform in the nature of a website through a global computer network; hosting of digital content on the Internet, namely, hosting of a database of medical images; software as a service (SAAS) featuring computer software platforms for image processing, storage and analysis in the fields of pharmaceuticals and biotechnology; conducting clinical trials for others at all stages and in various indications, particularly in oncology, neurology and systemic diseases; imaging contract research organization services and technology solutions, namely, non-medical ultrasound imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blinded independent central review of radiology images in the medical research and clinical trial setting for medical research and scientific research purposes; scientific research services, namely, integration of imaging results with clinical outcome data, with application of machine learning and artificial intelligence applications; development and evaluation in the nature of testing of imaging biomarkers for clinical trial purposes; software consulting services in the field of drug discovery; cloud computing featuring software for use in database management for use in pharmaceutical drug research in the field of drug discovery; radiochemistry services in the nature of radiolabeling for scientific research and medical research purposes and radiochemical analysis; research, development and testing services relating to radiopharmaceuticals; radiolabeling scientific research, namely, labeling of both small molecules and biologics; providing non-downloadable web-based computer software for database management in the fields of medical imaging, pharmaceutical and biotechnology research; medical imaging and radiology services related to drug development, namely, medical imaging and radiology services of clinical trial patients for research purposes; medical and scientific research services in the fields of magnetic resonance and molecular imaging; medical research services, in particular services relating to the development of radiotherapeutics and drug candidates for neurodegenerative diseases and precision oncology; image analysis and radiology, namely, analysis of images from all radiological modalities, such as but not limited to CT, MRI and PET scans, to provide quantitative evaluation of drug candidates medical radiology, namely, molecular imaging, imaging utilizing radiopharmaceuticals for medical research and pharmaceutical development purposes; pathology services, namely, testing for research purposes in the fields of pharmaceuticals and biotechnology; pathology services for preclinical biomarker discovery research and clinical trials | ACTIVE | — |
| 044 | Medical imaging services; medical imaging and radiology services related to drug development, namely, medical imaging and radiology services of clinical trial patients for medical purposes; image analysis and radiology, namely, analysis of images from all radiological modalities, such as but not limited to CT, MRI and PET scans to provide quantitative evaluation of drug candidates medical radiology, namely, molecular imaging, imaging utilizing radiopharmaceuticals for the diagnosis and medical treatment of trial candidates; radiomics, namely, medical radiology services; medical imaging services, namely, medical imaging and extraction of imaging biomarkers; analysis of medical images, namely, medical analysis of medical images for diagnosis and treatment of persons in clinical trials | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Invicro, LLC
- Other trademarks owned by Invicro, LLC
- Other trademarks owned by Invicro, LLC
- Other trademarks in Class 009
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 26, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 26, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 1, 2025 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Jul 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 1, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 20, 2025 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 3, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 3, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 3, 2025 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 2, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Mar 2, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 2, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 19, 2024 | IUAF | USE AMENDMENT FILED | — |
| Dec 19, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 19, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Dec 19, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 20, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 20, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 20, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 20, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 13, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 13, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 13, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 13, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 13, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 22, 2024 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| May 22, 2024 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Dec 15, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 13, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 13, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 13, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 20, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 25, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 25, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 5, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 17, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 17, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 17, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 17, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 17, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 13, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 13, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2023 | ALIE | ASSIGNED TO LIE | — |
| Jan 11, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 11, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 11, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 11, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 11, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 29, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 6, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 6, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 6, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 6, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 6, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 29, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 19, 2021 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 18, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 11, 2021 | NWAP | NEW APPLICATION ENTERED | — |